The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...

Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...

A non-invasive, high-accuracy surveillance test for bladder cancer has the potential to improve patient experience, streamline workflows, and reduce overall cost of care” — Megann Vaughn Watters, Vice ...

Explore new findings on bladder cancer and inflammation's role in immune suppression. Discover insights to improve treatment.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BERLIN — For years, scientists have held out hope that tests that look ...

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a ...

Khaberni - A number of researchers from the College of Medicine at Stanford University, Columbia University, and Beaumont ...